In this Covid Medical Grand Rounds, we’ll update the science and epidemiology of Long Covid, with three of the nation’s leading experts on the topic. We’ll cover new findings about the mechanisms by which Long Covid causes symptoms, progress in trying to identify effective treatments, and our growing understanding regarding the impact of Covid infections on long-term health outcomes.

Speakers
Ziyad Al-Aly, MD, is chief of the Research and Development Service and director of the Clinical Epidemiology Center at the VA Saint Louis Health Care System, as well as a clinical epidemiologist at Washington University. He serves on the White House Intra-agency Policy Committee on Long Covid, co-chaired the Biden-Harris Administration committee that developed the U.S. Government National Research Action Plan on Long Covid and serves on the Federal Government Long Covid Coordination Council. He has had numerous publications in Nature regarding the long-term impacts of Covid.

Akiko Iwasaki, PhD, is a professor of immunobiology at the Yale University School of Medicine. A leading scientific voice during the Covid-19 pandemic, she is also known for her advocacy on women and underrepresented minorities in science and medicine. Akiko is the director of the Center for Infection and Immunity and is at the forefront of several Long Covid investigations including the Mount-Sinai Yale Long Covid study, Yale LISTEN study, and Yale Paxlovid trial. She has been elected to the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences.

Michael Peluso, MD, is an infectious disease physician at ZSFG. When the SARS-CoV-2 pandemic emerged, he led the efforts to implement the Long-term Impact of Infection with Novel Coronavirus (LIINC) study examining Covid’s long-term effects on health. LIINC became one of the first studies focused on understanding the biological mechanisms that drive Long Covid and has supported over 50 scientific collaborations. Through LIINC, Michael now leads a Long Covid clinical trials program. He also oversees the implementation of the NIH’s RECOVER initiative at UCSF.

Note: Closed captions will be available within 48-72 hours after posting.

Program
Bob Wachter: Introduction
00:04:49-00:14:13 – Ziyad Al-Aly, MD, chief of the Research and Development Service and director of the Clinical Epidemiology Center at the VA Saint Louis Health Care System, clinical epidemiologist at Washington University
00:14:25-00:28:20 – Michael Peluso, MD, infectious disease physician at ZSFG
00:28:30-00:45:08 – Akiko Iwasaki, PhD, professor of immunobiology at the Yale University School of Medicine
00:45:18-1:03:02 – Q&A

See previous Medical Grand Rounds:

• November 30: Updates in TB: From Basic Science to Global Health Policy
   • Updates in TB: From Basic Science to ...  
• November 16: Updates in Addiction Medicine: Overdose Reduction, Equity, and Innovations in Care Delivery
   • Updates in Addiction Medicine: Overdo...  
• November 9: 2023 Updates in Anticoagulation
   • 2023 Updates in Anticoagulation  
• October 26: Bridging Synthetic Immunology and Genome Editing to Advance CAR-T Cell Therapies
   • Bridging Synthetic Immunology and Gen...